Bright Minds Biosciences Inc $DRUG

Recent News (20)

• ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug stocktwits.com · 05 Sep 2026 ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug  stocktwits.com
• Bright Minds Biosciences to Present at Upcoming Conferences GlobeNewswire · 04 Sep 2026 NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2…
• Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP PR Newswire · 04 Sep 2026 MUMBAI, India and NAPLES, Fla., Sept. 4, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that …
• European drug regulator reviews injectable iron medicines Investing.com · 04 Sep 2026 European drug regulator reviews injectable iron medicines
• Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms GlobeNewswire · 04 Sep 2026 First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilu…
• Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate PR Newswire · 04 Sep 2026 FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development ALAMEDA, Calif. and TAIPEI, Sept. 4, 2026 /PRNewswire/ -- Acepodi…
• Wells Fargo raises Amgen stock price target to $435 on drug trial outlook Investing.com · 04 Sep 2026 Wells Fargo raises Amgen stock price target to $435 on drug trial outlook  Investing.com
• Wells Fargo raises Amgen stock price target to $435 on drug trial outlook Investing.com Nigeria · 04 Sep 2026 Wells Fargo raises Amgen stock price target to $435 on drug trial outlook  Investing.com Nigeria
• Wells Fargo raises Amgen stock price target to $435 on drug trial outlook Investing.com India · 04 Sep 2026 Wells Fargo raises Amgen stock price target to $435 on drug trial outlook  Investing.com India
• MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership Stocktwits · 04 Sep 2026 MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership  Stocktwits
• C4X Discovery to receive milestone payment for NRF2 exclusive worldwide license agreement GlobeNewswire · 04 Sep 2026 4 September 2026 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it will receive a $13 million milestone payment from AstraZeneca [LON: AZN], triggered…
• Vivani Medical Announces Participation in Upcoming Investor Conferences GlobeNewswire · 03 Sep 2026 ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-actin…
• Xenon to Present at Wells Fargo Healthcare Conference GlobeNewswire · 03 Sep 2026 VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical dev…
• World Class Health Launches Infusion Care, Bringing Specialty Drug Treatments Home and Cutting Employer Costs by Roughly 46% PR Newswire · 03 Sep 2026 Employees on over 270 specialty infusions covering 95% of commercial spend can now be treated at home, on their own schedule and at no additional cost, while their employer pays a fraction of hospital…
• Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop. Yahoo Finance · 03 Sep 2026 Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop.
• Kali Therapeutics Receives U.S. FDA Clearance for KT501 Investigational New Drug Application PR Newswire · 03 Sep 2026 IND clearance enables U.S. clinical development of KT501, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager for B cell–mediated autoimmune diseases, building on safety data generated in the o…
• Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate Seeking Alpha · 03 Sep 2026 Pfizer, Medicus ink licensing deal worth up to $1B for antibody drug conjugate  Seeking Alpha
• Cellipont Bioservices' Texas Facility Has Supported Six Client Projects Expected to Reach IND Submission in 2026 PR Newswire · 03 Sep 2026 THE WOODLANDS, Texas, Sept. 3, 2026 /PRNewswire/ -- Cellipont Bioservices, a cell therapy contract development and manufacturing organization, today announced that its Texas facility has supported six…
• AbbVie posts trial win for multiple myeloma drug (ABBV) Seeking Alpha · 03 Sep 2026 AbbVie posts trial win for multiple myeloma drug (ABBV)  Seeking Alpha
• AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 PR Newswire · 03 Sep 2026 AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton va…